Social Europe

  • EU Forward Project
  • YouTube
  • Podcast
  • Books
  • Newsletter
  • Membership

What when there’s a vaccine?

Stuart Blume and Maurizia Mezza 15th May 2020

Amid the accelerated scientific quest for a vaccine against the coronavirus, crucial ethical and social questions have not yet been addressed.

vaccine
Stuart Blume

Each day brings reports of progress toward a coronavirus vaccine. As millions struggle with separation, loss of income, isolation and fear for vulnerable loved ones, the prospect of a vaccine offers courage and hope.

Vaccination has indeed saved countless lives and has been a cornerstone of public health for more than half a century. Currently 120 candidate vaccines against the coronavirus are under development, of which eight have entered human trials. One or more will almost certainly become available—not this year, hopefully next. But what then?

vaccine
Maurizia Mezza

How the vaccine is to be deployed may seem a trivial question compared with the urgency of today. Just a few months ago the only vaccination-related concern seemed to be the reluctance of some parents to have their child vaccinated.

Nevertheless, the history of recent vaccination campaigns shows that introducing a new vaccine is rarely unproblematic. It is best to clarify potential problems before solving them becomes itself a matter of urgency.

Two scenarios

When a vaccine is licensed, what are these problems likely to be? Over the months to come we can imagine two scenarios.



Don't miss out on cutting-edge thinking.


Join tens of thousands of informed readers and stay ahead with our insightful content. It's free.



In the first, optimistic, scenario, a combination of hygienic, social and therapeutic measures will have brought the epidemic under control. There will be no dreaded ‘second wave’. When the vaccine becomes available, people will view Covid-19 as akin to the flu. In Europe, rates of vaccination against seasonal influenza among over-65s vary hugely between countries: from less than 20 per cent to nearly 80 per cent.

When the human papilloma virus (HPV) vaccine was introduced, not only were initial vaccination rates lower than expected but here too huge differences emerged between countries. In Scotland in 2012 86.4 per cent of the target population (of adolescent girls) were vaccinated, but in Greece only 9 per cent. This was partly explicable in terms of how vaccination was organised—school-based programmes achieved higher rates. But sometimes girls were cajoled, threatened or bullied into getting themselves vaccinated.

Will it matter if there is little demand for the vaccine? The answer depends on the coverage needed for ‘herd immunity’. If enough people are immune, whether from vaccination or recovery, circulation of the virus is restricted. Unvaccinated people are then protected. The threshold percentage varies from one virus to another and may be around 70 per cent for the SARS-CoV-2 virus. It does matter.

Reports of responses to current social-distancing rules give some idea of the groups in which coverage might be problematically low: young people who regard themselves as low-risk, whole regions in which the state is viewed with suspicion and communities cut off by language or detained in overcrowded refugee camps. If adequate coverage is not achieved, what then? What measure of compulsion is acceptable?

Supply outstripped

In a second scenario the epidemic will have re-emerged. People are again dying. Everyone is clamouring to be vaccinated.

But the new vaccine is expensive and there is too little of it. Most of the institutions with vaccines already in human trials are small biotech firms. Production will gear up gradually and for months international demand will outstrip supply. Poor countries with weak health systems will be pushed to the back of the queue—however great their need.

This is what happened with HPV vaccines when they first became available in 2006. Four-fifths of the women affected by an HPV-related disease live in low and middle-income countries. But at $360 per capita for the required three shots these countries could not afford the vaccines at the time.

The introduction of the H1N1 flu vaccine in 2009 is also illuminating. When H1N1 was declared a pandemic, advance purchase contracts were automatically activated. Wealthy countries had paid an annual subscription to maintain these, sometimes with more than one manufacturer. They then had prior claim on a limited supply, though still only part of what they had ordered. Many countries subsequently developed guidelines, anticipating a future influenza pandemic.

Under such guidelines, priority should be given to healthcare workers and to people at greatest medical risk—as in respect of the coronavirus epidemic. But where regional sentiments are strong the most affected regions might claim priority or, elsewhere, insist that supplies should be equitably distributed among regions.

What has to be avoided at all costs is the nationalistic pushing and shoving which has taken place in recent weeks over ventilators and diagnostic tests. Can acceptable rationing criteria be found, so political haggling is later avoided?

Contract secrecy

Experience with the H1N1 vaccine a decade ago highlights something else. Although not public knowledge at the time, it emerged that many contracts absolved manufacturers of any obligation in respect of vaccine-related complications or side-effects. And such complications did arise: in Sweden and Finland, for example, cases of narcolepsy were found to be associated with one of the influenza vaccines used to control the pandemic.

Three of the eight candidate vaccines now in human trials make use of genetic material from the virus. The underlying technology has never been proven in a licensed human vaccine. There will be pressure to fast-track a coronavirus vaccine. Since there will not have been time to test it in all population groups, side-effects might again emerge.

An acceptable division of responsibility between states and manufacturers in the event of this happening needs to be established. Can the European Union use its bargaining power to negotiate contracts on behalf of member states, while not forgetting the interests of poor member (and non-member) countries?

None of this is to cast the slightest doubt on the crucial value of a coronavirus vaccine. But whatever our hopes, the licensing of a safe and effective vaccine will still leave difficult issues of accessibility, acceptability and responsibility—which need to be debated.

An earlier version of this article appeared in Italian in Il Manifesto

Stuart Blume
Stuart Blume

Stuart Blume is emeritus professor of science and technology studies at the University of Amsterdam and author of Immunization: How Vaccines Became Controversial (Reaktion Books, 2017).

Maurizia Mezza
Maurizia Mezza

Maurizia Mezza is a doctoral candidate in medical anthropology at the University of Amsterdam, focusing on epidemiological studies and pharmacovigilance in relation to HPV and Covid-19 vaccination.

Harvard University Press Advertisement

Social Europe Ad - Promoting European social policies

We need your help.

Support Social Europe for less than €5 per month and help keep our content freely accessible to everyone. Your support empowers independent publishing and drives the conversations that matter. Thank you very much!

Social Europe Membership

Click here to become a member

Most Recent Articles

u4219834670 4977 8362 2b68e3507e6c 2 Europe’s Far Right Copies Trump—And It’s WorkingPaul Mason
u421983467645c be21 1cdd415d1c01 2 America’s Systemic Chaos Strategy: Europe Must Forge a New PathMario Pianta
u42198346ae 124dc10ce3a0 0 When Ideology Trumps Economic InterestsDani Rodrik
u4219834676e9f0d82cb8a5 2 The Competitiveness Trap: Why Only Shared Prosperity Delivers Economic Strength—and Resilience Against the Far RightMarija Bartl

Most Popular Articles

u4219834647f 0894ae7ca865 3 Europe’s Businesses Face a Quiet Takeover as US Investors CapitaliseTej Gonza and Timothée Duverger
u4219834674930082ba55 0 Portugal’s Political Earthquake: Centrist Grip Crumbles, Right AscendsEmanuel Ferreira
u421983467e58be8 81f2 4326 80f2 d452cfe9031e 1 “The Universities Are the Enemy”: Why Europe Must Act NowBartosz Rydliński
u42198346761805ea24 2 Trump’s ‘Golden Era’ Fades as European Allies Face Harsh New RealityFerenc Németh and Peter Kreko

Eurofound advertisement

Ageing workforce
The evolution of working conditions in Europe

This episode of Eurofound Talks examines the evolving landscape of European working conditions, situated at the nexus of profound technological transformation.

Mary McCaughey speaks with Barbara Gerstenberger, Eurofound's Head of Unit for Working Life, who leverages insights from the 35-year history of the European Working Conditions Survey (EWCS).

Listen to the episode for free. Also make sure to subscribe to Eurofound Talks so you don’t miss an episode!

LISTEN NOW

Foundation for European Progressive Studies Advertisement

Spring Issues

The Summer issue of The Progressive Post is out!


It is time to take action and to forge a path towards a Socialist renewal.


European Socialists struggle to balance their responsibilities with the need to take bold positions and actions in the face of many major crises, while far-right political parties are increasingly gaining ground. Against this background, we offer European progressive forces food for thought on projecting themselves into the future.


Among this issue’s highlights, we discuss the transformative power of European Social Democracy, examine the far right’s efforts to redesign education systems to serve its own political agenda and highlight the growing threat of anti-gender movements to LGBTIQ+ rights – among other pressing topics.

READ THE MAGAZINE

Hans Böckler Stiftung Advertisement

WSI Report

WSI Minimum Wage Report 2025

The trend towards significant nominal minimum wage increases is continuing this year. In view of falling inflation rates, this translates into a sizeable increase in purchasing power for minimum wage earners in most European countries. The background to this is the implementation of the European Minimum Wage Directive, which has led to a reorientation of minimum wage policy in many countries and is thus boosting the dynamics of minimum wages. Most EU countries are now following the reference values for adequate minimum wages enshrined in the directive, which are 60% of the median wage or 50 % of the average wage. However, for Germany, a structural increase is still necessary to make progress towards an adequate minimum wage.

DOWNLOAD HERE

S&D Group in the European Parliament advertisement

Cohesion Policy

S&D Position Paper on Cohesion Policy post-2027: a resilient future for European territorial equity

Cohesion Policy aims to promote harmonious development and reduce economic, social and territorial disparities between the regions of the Union, and the backwardness of the least favoured regions with a particular focus on rural areas, areas affected by industrial transition and regions suffering from severe and permanent natural or demographic handicaps, such as outermost regions, regions with very low population density, islands, cross-border and mountain regions.

READ THE FULL POSITION PAPER HERE

ETUI advertisement

HESA Magazine Cover

With a comprehensive set of relevant indicators, presented in 85 graphs and tables, the 2025 Benchmarking Working Europe report examines how EU policies can reconcile economic, social and environmental goals to ensure long-term competitiveness. Considered a key reference, this publication is an invaluable resource for supporting European social dialogue.

DOWNLOAD HERE

Social Europe

Our Mission

Team

Article Submission

Advertisements

Membership

Social Europe Archives

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Miscellaneous

RSS Feed

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641

BlueskyXWhatsApp